Search

Highlights from the SWG

Impactful activitiesGuideline development projectThe most relevant and impactful activities of the SWG include those related to the guideline development project. There were regular meetings with the Guidelines Expert Panel Committee.

Read more

Highlights from the SWG

Session on thrombocytopenias and platelet function disordersFull title‘Thrombocytopenias and platelet function disorders: Recent developments and perspectives in immune thrombocytopenia. ’

DateThe session took place as part of the EHA 2023 Congress. This was held from June 8–11, 2023.

Read more

Highlights from the SWG

SWG AML Annual Scientific MeetingThe most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.

Read more

Highlights from the SWG

The SWG:

Was involved with the European Medicines Agency (EMA) on shortages—as part of our policy and regulatory work
Participated in the EMA Healthcare Professionals Policy Officers' Group (HCP POG) review of the ‘Frailty and Older People: Considerations in Medicine Development and…

Read more

Highlights from the SWG

SWG Committee meetingsIn 2023, the SWG Committee held meetings on:

February 21, 2023—online
April 6, 2023—in The Hague
June 8, 2023—at the EHA Congress 2023 in Frankfurt
In addition, an SWG Chairs and Committee Meeting was held on September 29, 2023, in The Hague.…

Read more

Highlights from the SWG

Most impactful activitiesHIV Registry (NCT05231135)This unique retrospective and prospective EHA LyG European registry was initiated in August 2021, but recruitment was stalled due to objections from the local Ethics Committee.

Read more

Highlights from the SWG

Joint work with the International Society on Thrombosis and Haemostasis (ISTH), the European Association for Haemophilia and Allied Disorders (EAHAD), and the European Stroke Organisation (ESO) to produce guidance on antithrombotic treatment in patients with hemophilia.

Read more

Highlights from the SWG

Project groupsPan-European Transfusion Research infrAstructure (PETRA) projectThe European Blood Alliance has provided funding for a health science data project entitled: ‘Towards a Pan-European Transfusion Research infrAstructure (PETRA).

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

New data exchange platform on rare diseases

The European Commission (EC) launched a new online knowledge-sharing platform – the European Platform on Rare Disease Registration (EU RD Platform) – on February 28, 2019.

Read more